Zynex admits to health care fraud scheme, agrees to pay DOJ millions

A Colorado-based medical device company, Zynex Inc., has reached an agreement with the U.S. Department of Justice to resolve allegations of a widespread healthcare fraud scheme. The scheme involved the overbilling of patients and insurers, resulting in potentially hundreds of millions of dollars in fraudulent claims.

Details of the Agreement

Zynex, headquartered in Englewood, Colorado, manufactures and sells devices used for pain management and rehabilitation. To avoid prosecution, the company has agreed to pay between $5 million and $12.5 million in penalties. The final amount will be determined based on Zynex’s earnings and profit during the settlement period. Zynex will forfeit millions of dollars in previously submitted, unpaid claims.

The Scope of the Fraud

According to the U.S. Attorney’s Office for the District of Rhode Island, Zynex admitted to participating in a conspiracy involving healthcare fraud, securities fraud, and mail fraud, among other violations. Investigators determined that the company collected over $873 million for its products, with more than $600 million of that total stemming from supplies obtained through fraudulent means.

Did You Know? Two former top Zynex executives were indicted by a federal grand jury last month, accused of leading the years-long fraudulent scheme.

The company acknowledged shipping and billing for supplies that were not medically necessary, often in excessive quantities. Zynex also admitted to misleading investors by failing to disclose these fraudulent billing practices.

Compliance and Future Outlook

As part of the agreement, Zynex is required to implement significant reforms to its compliance and corporate governance procedures. These changes are intended to prevent future misconduct. The company has also pledged full cooperation with ongoing government investigations.

U.S. Attorney Charles C. Calenda stated that the resolution acknowledges both the severity of the fraud and the “substantial turnaround in conduct” implemented by the new management team. Zynex’s new leadership, which took over in August 2025, has stated its commitment to rebuilding the company with a focus on compliance and integrity. They report having overhauled billing practices, supply replenishment procedures, and marketing policies to align with U.S. Food and Drug Administration regulations.

Expert Insight: This case highlights the critical importance of robust oversight and ethical practices within the medical device industry. The potential for financial gain can create incentives for fraudulent behavior, underscoring the need for strong regulatory enforcement and internal controls to protect patients and the integrity of the healthcare system.

Zynex’s cooperation with the government could lead to a more lenient outcome in the ongoing investigations. However, the full extent of the financial and legal repercussions remains to be seen.

Frequently Asked Questions

What specific types of fraud did Zynex engage in?

Zynex admitted to participating in a conspiracy to commit healthcare fraud, securities fraud, and mail fraud. Specifically, they shipped and billed for medically unnecessary supplies in excess quantities and misled investors.

How much money is Zynex potentially liable for?

Zynex has agreed to pay between $5 million and $12.5 million in penalties, with the final amount dependent on its future earnings. They will also forfeit millions of dollars in unpaid claims.

What changes is Zynex making to prevent future fraud?

Zynex has agreed to implement enhanced compliance and corporate governance reforms. They have also overhauled their billing and supply replenishment practices and enacted new marketing policies.

As Zynex moves forward under new leadership, what role do you believe increased transparency and ethical conduct will play in restoring trust with patients and insurers?